Myelodysplastic syndromes (MDS) are cancers that are a bone marrow failure resulting in the lack of healthy blood cell production. Some patients with MDS can develop acute myelogenous leukemia. Our team of experts provide world class treatment for patients with MDS and leukemia.
Myelodysplastic Syndromes treated at Nebraska Medicine
- Refractory cytopenia with unilineage dysplasia (RCUD)
- Refractory anemia with ringed sideroblasts (RARS)
- Refractory cytopenia with multilineage Dysplasia (RCMD)
- Refractory anemia with excess blasts-1 (RAEB-1)
- Refractory anemia with excess blasts-2 (RAEB-2)
- Myelodysplastic syndrome, unclassified (MDS-U)
- Myelodysplastic syndrome associated with isolated del(5q)
Risk Factors
Some of the risk factors for developing MDS may include age, family history, smoking tobacco, exposure to certain chemicals, prior radiation therapy and chemotherapy. Common symptoms may include: fatigue, shortness of breath, easy bleeding and bruising, frequent and recurring infection. The majority of patients are 60 or older however, MDS can be seen in younger populations.
Leading Edge Treatment at Nebraska Medicine
- Chemotherapy
- Growth factors
- Immunosuppressive therapy
- Stem cell transplantation
- Supportive therapy / blood transfusions
Access to the Most Advanced Treatments
Our team of cancer experts are extremely active in clinical research and clinical trials, providing you with access to the most up-to-date and revolutionary treatments.
We are part of the National Institutes of Health/National Cancer Institute Blood and Marrow Transplant Clinical Trials Network – a consortium transplant centers across the country that collaborate on clinical trials in order to derive data from a larger population of patients and to allow for greater sharing of information between centers.
Through this network, doctors can study and refine their techniques to diagnose, treat and follow patients to provide them with optimal care.
Our doctors and researchers are internationally known for their breakthroughs in this area and offer you access to the newest and most innovative therapies through our participation in clinical trials. See what clinical trials related to myelodysplastic syndromes are currently underway.
Fred & Pamela Buffett Cancer Center, Revolutionizing Cancer Care
We’re revolutionizing cancer care, using your own genetic identity to create the most targeted care plan, and offering more lifesaving clinical trials and technology.
As part of our ongoing effort to provide you with the latest cancer treatments close to home, in June 2017 we opened the Fred & Pamela Buffett Cancer Center at Nebraska Medicine — one of the foremost research and treatment centers in the nation.
Regardless of which of our four locations you’re being seen at, extraordinary care is just a short drive from home. All patients undergoing cancer treatment at Nebraska Medicine also have access to our 24/7 Infusion Center at the Fred & Pamela Buffett Cancer Center, which serves as both a treatment center and around-the-clock urgent-care-type facility for those battling cancer. A rare offering in the region.